The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, an industry leader in artificial intelligence for drug discovery and development, today announced the appointment of Sharath Hegde, Ph.D. as its Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results